Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical CollegefiledCriticalHampton Roads Medical College
Priority to NO984725ApriorityCriticalpatent/NO984725L/en
Publication of NO984725D0publicationCriticalpatent/NO984725D0/en
Publication of NO984725LpublicationCriticalpatent/NO984725L/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Depot-administreringsavlevering av antiprogestin unngår den uønskede perifere virkningen, spesielt den på ACTH/kortisolaksen. En effektiv mengde av antiprogestinet administreres og adsorberes/absorberes av den omgivende vev. Det terapeutiske resultatet innbefatter langvarig, men reversibel, amenore.Depot administration delivery of antiprogestin avoids the undesirable peripheral effect, especially that on the ACTH / cortisol axis. An effective amount of the antiprogestin is administered and adsorbed / absorbed by the surrounding tissue. The therapeutic result includes prolonged, but reversible, amenorrhea.
Active ingredient combinations of polyhexamethylenebiguanidine hydrochloride and distearyldimethylammonium chloride and preparations comprising said active ingredient combinations